NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
A Company to watch in China - potential customer for HLS

Beijing-based Lotus Pharmaceuticals is working on an ambitious strategy with a Wall Street financial advisor that can potentially catapult the company right into China's top pharma league with annual revenues exceeding $100 million.


Dr Liu Zhongyi, CEO of Lotus Pharmaceuticals, said, "We have targeted the acquisition of a Beijing company that is a major drug supplier to 99 percent of the 'Triple A' hospitals in Beijing (the highest grade hospitals in China), and to 90 percent of the 'Double A' hospitals in Beijing. These dominant market positions are valuable to Lotus to market its current drug products as well as reselling new drugs from overseas pharmaceutical companies. If completed, this acquisition could add about $100 million to Lotus's annual revenues."

Lotus is taking the inorganic path to growth, besides the above, the company is also eyeing a pharmaceutical manufacturing and marketing company in South China. This company had revenues of about $9 million last year, with a 20 percent profit margin. With this acquisition, Lotus can get access to the company's 30 new drugs approved by SFDA, which have a very strong market prospect.

"With appropriate financing, our strategy is that, by acquiring these two companies, Lotus will establish itself as one of the major pharmaceutical companies with much expanded marketing channels and a good range of products, plus a superb R&D capability. The revenue expansion comes from selling a range of both high turn-around products and new and effective drugs through the much-expanded marketing channels," added Dr Liu.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.